The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IASLC TTLC 2022 | Updates in the SCLC treatment landscape
Triparna Sen
• 21 Feb 2022
Triparna Sen, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses upcoming small cell lung cancer (SCLC) trials assessing novel targets, including lysine-specific histone demethylase 1A (LSD1) inhibitors, enhancer of zeste homolog 1/2 (EZH1/2) inhibitors and DNA damage response inhibitors. This interview took place at the 2022 Targeted Therapies of Lung Cancer Meeting (TTLC 2022).
